Kurt Landgraf, newly appointed CEO of Du Pont Merck Pharmaceutical Co., addresses complaints of discrimination against African-American scientists in R & D with significant staff cuts and dramatic changes in the pharmaceutical industry.

Kurt Landgraf, newly appointed CEO of Du Pont Merck Pharmaceutical Co., addresses complaints of discrimination against African-American scientists in R & D with significant staff cuts and dramatic changes in the pharmaceutical industry.
«Hide

from
Mary Gentile,
Sarah B. Gant
Source: Harvard Business School
24 pages.
Release date: 01 June, 1994. Prod #: 394202-PDF-ENG
Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A) HBR case solution